Raphael Brandão Moreira

Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients

Guillermo de Velasco, Youjin Je, Dominick Bossé et al. · Cancer Immunology Research · 2017 · 476 citations · Full text

Medicine, Oncology, Pharmacology +17

The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma

Rana R. McKay, Dominick Bossé, Wanling Xie et al. · Cancer Immunology Research · 2018 · 136 citations · Full text

Medicine, Oncology, Pharmacology +17

Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

Steven Yip, J. Connor Wells, Raphael Brandão Moreira et al. · Cancer · 2018 · 66 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events

Dylan J. Martini, Lana Hamieh, Rana R. McKay et al. · Cancer Immunology Research · 2018 · 62 citations

Medicine, Oncology, Pharmacotherapy +17

The Development of Brain Metastases in Patients with Renal Cell Carcinoma: Epidemiologic Trends, Survival, and Clinical Risk Factors Using a Population-based Cohort

Maxine Sun, Guillermo de Velasco, Priscilla K. Brastianos et al. · European Urology Focus · 2018 · 58 citations

Medicine, Neurology, Oncology +15